TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38367207

Group type: EXPERIMENTAL
Intervention: 12-week timing and coordination physical therapy intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 42
Study: 38367405

Group type: EXPERIMENTAL
Intervention: On-treatment modified Glasgow prognostic score (mGPS) assessed at week six in atezolizumab-treated subgroup
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: On-treatment modified Glasgow prognostic score (mGPS)
Number of subjects: 750
Study: 38367595

Group type: EXPERIMENTAL
Intervention: Sleep Low-No Carbohydrates (SL-NCHO)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sleep High-Low Glycemic Index (SH-LGI)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sleep High-High Glycemic Index (SH-HGI)
Number of subjects: 42
Study: 38367643

Group type: EXPERIMENTAL
Intervention: solar-powered O
Number of subjects: 2405
Study: 38367686

Group type: EXPERIMENTAL
Intervention: Microfluidics sperm processing
Number of subjects: 106

Group type: COMPARATOR
Intervention: Density gradient centrifugation
Number of subjects: 106
Study: 38367687

Group type: EXPERIMENTAL
Intervention: PGT-A
Number of subjects: 1212

Group type: COMPARATOR
Intervention: IVF-ET
Number of subjects: 1212
Study: 38367749

Group type: EXPERIMENTAL
Intervention: Early amniotomy (rupture of membranes within 2 hours after Foley balloon removal)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Delayed amniotomy (rupture of membranes performed more than 4 hours after Foley balloon removal)
Number of subjects: 149
Study: 38367750

Group type: COMPARATOR
Intervention: 25 μg vaginal misoprostol
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 50 μg vaginal misoprostol
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 50 μg vaginal misoprostol (subgroup: multiparous patients)
Number of subjects: 180

Group type: COMPARATOR
Intervention: 25 μg vaginal misoprostol (subgroup: multiparous patients)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups (25 μg and 50 μg)
Number of subjects: 180
Study: 38367767

Group type: EXPERIMENTAL
Intervention: Experiencing racial discrimination
Number of subjects: 344
Study: 38367831

Group type: EXPERIMENTAL
Intervention: Early bedside cycling in addition to inpatient cardiac rehabilitation (CR) program
Number of subjects: 31
Study: 38367968

Group type: EXPERIMENTAL
Intervention: ONCORAL programme follow-up
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study: 38367966

Group type: EXPERIMENTAL
Intervention: Nudge intervention consisting of three text message reminders with four behavioural nudges: (1) social norm messages, (2) different messengers through links to short educational videos, (3) a pledge to have their child vaccinated, (4) information salience through links to guidelines and vaccine safety information.
Number of subjects: 2076

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 2076
Study: 38367972

Group type: EXPERIMENTAL
Intervention: Semi-annual ultrasound (US) and abbreviated liver MRI (AMRI)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Semi-annual ultrasound (US) alone
Number of subjects: 944
Study: 38367973

Group type: EXPERIMENTAL
Intervention: baby HABIT-ILE intervention (50 hours over 2 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: baby HABIT-ILE intervention (after 3-month assessment)
Number of subjects: 48
Study: 38368175

Group type: EXPERIMENTAL
Intervention: 4D flow MRI
Number of subjects: 64
Study: 38368278

Group type: EXPERIMENTAL
Intervention: Ongoing anal incontinence (AI)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Passed or ongoing episodes of AI
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Quality of life impact due to AI
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Post-obstetrical AI ≥ 6 months (POAI ≥ 6)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Instrumental birth as a protective factor for POAI ≥ 6
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Parity as a risk factor for POAI ≥ 6
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: BMI as a risk factor for POAI ≥ 6
Number of subjects: 227
Study: 38368316

Group type: EXPERIMENTAL
Intervention: Online video-assisted education on breastfeeding
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 38368355

Group type: EXPERIMENTAL
Intervention: Clip-reconstruction
Number of subjects: 880

Group type: COMPARATOR
Intervention: Endovascular treatment
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Regular care during hospital stay
Number of subjects: 880
Study: 38368409

Group type: EXPERIMENTAL
Intervention: Snare tip soft coagulation (STSC) of the entire resection margin after EMR
Number of subjects: 306

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Snare tip soft coagulation (STSC)
Number of subjects: 306
Study: 38368495

Group type: EXPERIMENTAL
Intervention: Ischemia-modified albumin (IMA)
Number of subjects: 113
Study: 38368518

Group type: EXPERIMENTAL
Intervention: Post-thaw extended culture blastocysts
Number of subjects: 182

Group type: COMPARATOR
Intervention: Thawed cleavage-stage ET
Number of subjects: 182
Study: 38368603

Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Daily GH (0.034 mg/kg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/week) after continuous treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/week) after switch from daily GH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Somapacitan
Number of subjects: 30
Study: 38368846

Group type: EXPERIMENTAL
Intervention: Awake prone positioning
Number of subjects: 475
Study: 38368901

Group type: EXPERIMENTAL
Intervention: Targeted anticoagulation according to TRiP(cast) score (no prescription if score <7, anticoagulation if score ≥7)
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Control phase (anticoagulation prescription according to physician's usual practice)
Number of subjects: 1505
Study: 38369126

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (E-EN)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Early supplemental parenteral nutrition (E-SPN)
Number of subjects: 314
Study: 38369221

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 98
Study: 38369233

Group type: EXPERIMENTAL
Intervention: Parenteral thiamine (100 mg daily) for ≥3 days
Number of subjects: 449

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 449
Study: 38369238

Group type: EXPERIMENTAL
Intervention: Triage blood pressure measurements
Number of subjects: 130
Study: 38369267

Group type: EXPERIMENTAL
Intervention: 8-week interdisciplinary weight loss and lifestyle intervention
Number of subjects: 89
Study: 38369528

Group type: EXPERIMENTAL
Intervention: Ringer's acetate solution (RAS)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: RAS-only
Number of subjects: 143

Group type: COMPARATOR
Intervention: NSS-only
Number of subjects: 143
Study: 38369573

Group type: EXPERIMENTAL
Intervention: PRV-101 (low dose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PRV-101 (high dose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PRV-101 (low dose and high dose)
Number of subjects: 32
Study: 38369805

Group type: EXPERIMENTAL
Intervention: Salvage treatment (not specified, but includes proteasome inhibitor-based combination therapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Proteasome inhibitor (PI)-based combination therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Second BCMA CAR-T (including LCAR-B38M)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Salvage therapy in patients with extramedullary disease at baseline
Number of subjects: 45
Study: 38369951

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 188
Study: 38370154

Group type: EXPERIMENTAL
Intervention: Impella
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IABP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38370536

Group type: COMPARATOR
Intervention: Moderate-increasing BMI trajectory
Number of subjects: 1824

Group type: COMPARATOR
Intervention: High-increasing BMI trajectory
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Higher BMI variability (measured by standard deviation)
Number of subjects: 1824
Study: 38370630

Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS combined with semantic feature analysis (SFA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS combined with semantic feature analysis (SFA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study: 38371194

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 159
Study: 38371290

Group type: EXPERIMENTAL
Intervention: 300 mg inclisiran sodium on days 1, 90, and 270
Number of subjects: 345

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 345
Study: 38371314

Group type: EXPERIMENTAL
Intervention: octocog alfa (prophylaxis)
Number of subjects: 711

Group type: COMPARATOR
Intervention: octocog alfa (on-demand therapy)
Number of subjects: 711
Study: 38371479

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg subcutaneously once weekly for 12 weeks
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo subcutaneously once weekly for 12 weeks
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 38371485

Group type: EXPERIMENTAL
Intervention: CRP-guided management
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care (guided by clinical findings only)
Number of subjects: 81
Study: 38372128

Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride 0.1% (Otrivin)
Number of subjects: 136
Study: 38372148

Group type: EXPERIMENTAL
Intervention: Surgical repair of proximal hamstring ruptures
Number of subjects: 12
Study: 38372592

Group type: EXPERIMENTAL
Intervention: Nutrition-Focused Physical Exam (NFPE) conducted by registered dietitian nutritionists (RDNs)
Number of subjects: 541
Study: 38372621

Group type: EXPERIMENTAL
Intervention: Double-dose dolutegravir (50 mg twice daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard-dose dolutegravir
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Double-dose dolutegravir
Number of subjects: 35
Study: 38372622

Group type: EXPERIMENTAL
Intervention: Propafenone (70 mg bolus followed by 400-840 mg/24 h)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 170

Group type: COMPARATOR
Intervention: Amiodarone (300 mg bolus followed by 600-1800 mg/24 h)
Number of subjects: 170
Study: 38372727

Group type: EXPERIMENTAL
Intervention: Cadonilimab 15 mg/kg every 3 weeks plus chemotherapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy and bevacizumab
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy and bevacizumab (combined with cohort A-10)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cadonilimab (all cohorts)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cadonilimab combined with standard therapy
Number of subjects: 45
Study: 38372798

Group type: EXPERIMENTAL
Intervention: Red palm olein (RPOO)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Extra virgin coconut oil (EVCO)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Extra virgin olive oil (EVOO)
Number of subjects: 156
Study: 38372904

Group type: EXPERIMENTAL
Intervention: Everolimus (oral daily for 52 weeks)
Number of subjects: 12
Study: 38372938

Group type: EXPERIMENTAL
Intervention: GSK2982772 (960 mg once-daily modified-release formulation)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 38372949

Group type: EXPERIMENTAL
Intervention: PY314 10 mg/kg in combination with pembrolizumab 200 mg IV every 21 days
Number of subjects: 17
Study: 38372981

Group type: EXPERIMENTAL
Intervention: Sublingual edaravone dexborneol (edaravone, 30 mg; dexborneol, 6 mg)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Placebo (edaravone, 0 mg; dexborneol, 60 μg)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Both groups (edaravone dexborneol and placebo)
Number of subjects: 914
Study: 38372998

Group type: EXPERIMENTAL
Intervention: Community-based maternal and newborn care services package
Number of subjects: 7598

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7598
Study: 38373025

Group type: EXPERIMENTAL
Intervention: S4E mHealth intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 38373029

Group type: EXPERIMENTAL
Intervention: iSMART intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Manual of stroke rehabilitation (attention control)
Number of subjects: 24
Study: 38373037

Group type: EXPERIMENTAL
Intervention: CT-MICART+EMAs for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: EMAs only for 6 weeks
Number of subjects: 50
Study: 38373429

Group type: EXPERIMENTAL
Intervention: Parental stroking before heel lance (intervention group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Parental stroking after heel lance (control group)
Number of subjects: 112
Study: 38373534

Group type: EXPERIMENTAL
Intervention: soul food vegan diet (n = 77)
Number of subjects: 159

Group type: COMPARATOR
Intervention: soul food omnivorous diet (n = 82)
Number of subjects: 159
Study: 38373596

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation in COPD patients receiving EBV
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Higher number of TTs
Number of subjects: 97
Study: 38373673

Group type: EXPERIMENTAL
Intervention: Automatic Mechanical Ventilation (MV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual Bag Ventilation (BV)
Number of subjects: 60
Study: 38373694

Group type: EXPERIMENTAL
Intervention: Yeast fermented (YF) bread made of bread wheat
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Yeast fermented (YF) bread made of spelt
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Yeast fermented (YF) bread made of emmer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sourdough fermented (SF) bread made of bread wheat
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sourdough fermented (SF) bread made of spelt
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sourdough fermented (SF) bread made of emmer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Yeast fermented (YF) breads overall
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sourdough fermented (SF) breads overall
Number of subjects: 40
Study: 38373818

Group type: EXPERIMENTAL
Intervention: Plantar compartment block
Number of subjects: 30
Study: 38373857

Group type: EXPERIMENTAL
Intervention: Early Detection and Treatment to Reduce Events with Agitation Tool (ED-TREAT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: ED-TREAT
Number of subjects: 26
Study: 38373864

Group type: EXPERIMENTAL
Intervention: Combined use of cardiac rhythm monitoring devices, echocardiography, biomarkers, and neuroimaging.
Number of subjects: 0
Study: 38373918

Group type: EXPERIMENTAL
Intervention: Pediatric Appendicitis Score (PAS) for PG group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Pediatric Appendicitis Score (PAS) for FG group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 124

Group type: COMPARATOR
Intervention: Pediatric Appendicitis Score (PAS) < 4
Number of subjects: 124

Group type: COMPARATOR
Intervention: Comparison of PAS scores between PG and FG
Number of subjects: 124
Study: 38373922

Group type: EXPERIMENTAL
Intervention: Very high positive, low negative trajectory
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: High positive, moderate negative trajectory
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Very high positive, moderate negative trajectory
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: High positive, high negative trajectory
Number of subjects: 215
Study: 38373934

Group type: EXPERIMENTAL
Intervention: Isokinetic training for 4 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Isotonic training for 4 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Home isometric exercise (control group) for 4 weeks
Number of subjects: 43
Study: 38373937

Group type: EXPERIMENTAL
Intervention: Pharmacist-led individualized review of pharmacotherapeutic plans
Number of subjects: 432

Group type: COMPARATOR
Intervention: Usual management practice
Number of subjects: 432
Study: 38373948

Group type: EXPERIMENTAL
Intervention: Positive fantasizing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Positive fantasizing and mindfulness
Number of subjects: 100
Study: 38374026

Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide (PTCy) 50 mg/kg/d at days +3 and +4 plus standard GVHD prophylaxis
Number of subjects: 89

Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG) 5 mg/kg plus standard GVHD prophylaxis
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide (PTCy)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 89
Study: 38374062

Group type: EXPERIMENTAL
Intervention: Metronomic trabectedin combined with low-dose cyclophosphamide
Number of subjects: 50
Study: 38374084

Group type: EXPERIMENTAL
Intervention: Screen-Free Time with Friends intervention
Number of subjects: 75
Study: 38374091

Group type: EXPERIMENTAL
Intervention: adjuvant trastuzumab
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: RNA-seq data as a surrogate
Number of subjects: 909
Study: 38374100

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention with implementation support for 18 months.
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group receiving the same implementation support after the intervention period.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Triadic sub-study involving patients, next of kin, and attending clinicians.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Clinical data and health register data collected from patients.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Questionnaire for clinical staff in both arms before and during the implementation period.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Qualitative interviews in intervention units with various stakeholders.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis evaluating resource utilization and costs.
Number of subjects: 420
Study: 38374103

Group type: EXPERIMENTAL
Intervention: ECMO-AI (ECMO-associated infections)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: ECMO-AI
Number of subjects: 602
Study: 38374126

Group type: EXPERIMENTAL
Intervention: FACE self-help app (active intervention group)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 250
Study: 38374149

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (O-3 + TRAIN group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Medium chain triglycerides (MCTs; TRAIN group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (O-3 + SEDEN group)
Number of subjects: 26
Study: 38374158

Group type: EXPERIMENTAL
Intervention: Walking outdoors
Number of subjects: 164

Group type: COMPARATOR
Intervention: Walking indoors
Number of subjects: 164
Study: 38374347

Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule)
Number of subjects: 42
Study: 38374568

Group type: EXPERIMENTAL
Intervention: Lactated Ringers (LR)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 76
Study: 38375038

Group type: EXPERIMENTAL
Intervention: Remimazolam combined with low dose esketamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol combined with low dose esketamine
Number of subjects: 0
Study: 38375072

Group type: EXPERIMENTAL
Intervention: Avocado-supplemented diet (1 avocado per day)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Avocado-supplemented diet
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 1008
Study: 38375411

Group type: EXPERIMENTAL
Intervention: Robotic gastric bypass (RGB)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Laparoscopic gastric bypass (LGB)
Number of subjects: 153
Study: 38375429

Group type: EXPERIMENTAL
Intervention: Inhaled APN01 (rhACE2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38375580

Group type: EXPERIMENTAL
Intervention: Intervention of Participation and Executive Functions (I-PEX) (n=13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treatment-as-usual (n=12)
Number of subjects: 25
Study: 38375637

Group type: EXPERIMENTAL
Intervention: Elevated donor-derived cell-free DNA (dd-cfDNA)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Elevated cell-free mitochondrial DNA
Number of subjects: 148
Study: 38375705

Group type: EXPERIMENTAL
Intervention: Frail group (n=42)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Nonfrail group (n=103)
Number of subjects: 145
Study: 38375882

Group type: COMPARATOR
Intervention: Smartphone app
Number of subjects: 2703
Study: 38375995

Group type: EXPERIMENTAL
Intervention: Lacosamide (8-12 mg/kg/day)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 255
Study: 38376015

Group type: EXPERIMENTAL
Intervention: Actigraphy device worn on the nondominant wrist for 21 days, recording CH attack-related data.
Number of subjects: 4
Study: 38376181

Group type: EXPERIMENTAL
Intervention: High-resolution spinal cord stimulation (HR-SCS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Commercial paddle leads
Number of subjects: 18